Pulmatrix, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Pulmatrix (market cap ~$25.2M) announced its merger with privately held Eos SENOLYTIX, a gerotherapeutics company developing MitoXcel peptides for aging-related diseases. The merger agreement was signed March 26, 2026; SEC S-4 registration became effective September 25, 2026, and stockholder approval obtained. Pulmatrix raised $1.0M gross proceeds in March 2026 via private placement of Series B Convertible Preferred Stock to an Eos affiliate. Cash position declined from $4.1M (Dec 2025) to $1.4M (Sept 2026); company halted clinical development pending asset licensing/monetization. Merger expected to close November 2026, subject to Nasdaq listing approval and reverse stock split completion (approved Oct 26, 2026).
Why this rating
Transformational event: merger would reshape company entirely, combining two asset platforms (iSPERSE + MitoXcel). Materially dilutive to existing shareholders via stock issuance; existential risk if deal fails. Major event relative to $25.2M market cap.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +1.43% over 4 hrs, n=54).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.32 | +10 min · unknown $1.32 ▲ 0.00% | +30 min · unknown $1.32 ▲ 0.00% | +1 hr · unknown $1.32 ▲ 0.00% | +4 hrs · unknown $1.34 ▲ 1.51% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.